NCT00674635 - Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

GSK3152314A

Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose

DRUG

Placebo

matching placebo

Trial Locations (19)

2001

GSK Investigational Site, Hamilton

3084

GSK Investigational Site, Heidelberg

4102

GSK Investigational Site, Woolloongabba

6035

GSK Investigational Site, Wellington

8011

GSK Investigational Site, Christchurch

11000

GSK Investigational Site, Belgrade

11080

GSK Investigational Site, Belgrade

18205

GSK Investigational Site, Niška Banja

69035

GSK Investigational Site, Zaporizhzhya

79013

GSK Investigational Site, Lviv

83114

GSK Investigational Site, Donetsk

115522

GSK Investigational Site, Moscow

129327

GSK Investigational Site, Moscow

150062

GSK Investigational Site, Yaroslavl

214018

GSK Investigational Site, Smolensk

630117

GSK Investigational Site, Novosibirsk

VIC 30004

GSK Investigational Site, Melbourne

03103

GSK Investigational Site, Kyiv

03680

GSK Investigational Site, Kyiv